Skip to content

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer: the LEaD Study. A Prospective Cohort Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02507180
Acronym
LEaD
Enrollment
366
Registered
2015-07-23
Start date
2015-09-30
Completion date
2022-01-31
Last updated
2020-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis, Pregnancy

Keywords

Clinical Decision Rule, Ultrasound, Suspected Deep Vein Thrombosis, D-Dimer, LEFt

Brief summary

This is prospective cohort study in pregnant women who present with signs and symptoms of possible deep vein thrombosis (DVT). All patients will have the same method of assessment of their DVT symptoms (the LEFt clinical decision rule will be applied and D-dimer test will be done) to determine if a compression ultrasound is required. All patients will be followed for a period of 3 months.

Detailed description

VTE is a leading cause of maternal death in the developed world. Suspected DVT in pregnancy is a common clinical problem faced by clinicians daily. The only validated method to exclude DVT in pregnancy requires leg vein CUS imaging. This imaging modality is costly and has limited availability (only available in radiology departments and, usually, only during weekday daytime hours) often necessitating referral to the emergency room for initiation of heparin injections until leg vein CUS can be obtained. A simple and seemingly powerful clinical decision rule (LEFt) and a simple blood test (D-dimer) may be promising to exclude DVT in pregnancy without the need for diagnostic imaging. Validating the safety of a simple, non-invasive, widely available approach to suspected DVT in pregnancy would be an important advance in maternal health. A prospective cohort diagnostic management study in pregnant women with suspected DVT, with three-month follow-up for symptomatic VTE will take place in multiple centres throughout Canada and Europe. After obtaining informed consent, all patient will have the LEFt clinical decision rule applied by the attending physician and will have D-Dimer testing (D-Dimer results of test performed within 24 hours will be accepted and do not need to be repeated). Patients with an unlikely LEFt score of 0 or 1 point and a negative D-dimer will not undergo diagnostic imaging. Patients with either a likely LEFt score of 2 or 3 points or a positive D-dimer will undergo either a single complete leg vein compression ultrasound (CCUS) (Day 1) or a serial proximal leg vein (CUS) (Day 1 and Day 7). All patients will be followed for 3 months for symptomatic VTE.

Interventions

OTHERLEFt clinical decision rule

The LEFt rule Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1 Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point

Sponsors

University Hospital, Geneva
CollaboratorOTHER
Leiden University Medical Center
CollaboratorOTHER
Ottawa Hospital Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Unselected pregnant women (as self-reported by patient and/or previously documented positive beta hCG on urine or serum pregnancy tests) with 2. Suspected acute symptomatic deep vein thrombosis, defined as: 1. New leg swelling or edema with onset in the last month or, 2. New leg pain (buttock, groin, thigh or calf) with onset in the last month.

Exclusion criteria

1. Below the age of legal consent in jurisdiction of residence (18 years old for Quebec and 16 years old for rest of Canada) 2. Baseline imaging (imaging done after a minimum of 3 months of treatment for prior proximal DVT) not available if suspected recurrence in the same leg as prior 3. Unable or unwilling to provide informed consent 4. Concomitant symptoms of suspected pulmonary embolism (chest pain or shortness of breath or syncope/pre-syncope or unexplained tachycardia) 5. Therapeutic anticoagulant more than 48 hours.

Design outcomes

Primary

MeasureTime frameDescription
Number of VTE diagnosed in patients deemed DVT unlikely3 months after presentationThe primary outcome will be the number of VTE (distal or proximal DVT, sub-segmental or greater pulmonary embolism (PE), death attributable to VTE) documented during the three-month follow-up in those patients left untreated for DVT on the basis of the study's initial diagnostic management (see Figure 2) i.e. not doing CUS on patients with an unlikely LEFt score (0 or 1 points) and a negative D-dimer

Secondary

MeasureTime frameDescription
Number of VTE diagnosed in all patients3 months after presentationThe number of major VTE events (any proximal DVT, segmental or greater PE, death attributable to VTE) documented during the 3-month follow-up in all patients. Some clinicians may not treat distal DVT or sub-segmental PE in pregnancy, instead following these patients with serial US imaging, and hence may prefer to focus on this outcome that excludes distal DVT and sub-segmental PE.
Proportion of women requiring CUSBaselineThe proportion of women requiring CUS using the study's diagnostic strategy (i.e. no imaging in patients with an unlikely LEFt score (0 or 1 points) and a negative D-dimer). We anticipate that an important proportion (\>40%) of women will be able to avoid the need for CUS imaging based on safely excluding DVT on the basis of an unlikely LEFt (0 or 1) and a negative D-dimer. However, if this proportion is very low (\<5%) this may argue against the widespread adoption of our proposed diagnostic management strategy even if it proves to be safe.
Average number of CUS in pregnant women with suspected DVT7 days from initial presentationThe mean number of ultrasounds per patient with suspected DVT. In the study by Chan, validating serial CUS in pregnancy, the mean number of US per patient was 2.8630. We anticipate that we will be able to reduce this by \>40% with our diagnostic approach.

Countries

Canada, Netherlands, Switzerland, United States

Contacts

Primary ContactMarc A Rodger, MD
marc.rodger@mcgill.ca514-843-1578
Backup ContactVeronica Bates, BSc
vebates@ohri.ca613-737-8899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026